Pharma News

Novartis announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials. Results show that Gilenya impacted four key measures of MS disease activity (relapses, MRI lesions, disability progression and brain shrinkage), in people with relapsing-remitting multiple sclerosis (RRMS) for up to 16 months. This is also the first time a multicenter study has evaluated and shown that routine magnetic resonance imaging (MRI) scans taken in the every-day clinical setting can reliably be used to measure brain shrinkage, a key measure of disease progression, in people with RRMS. Full results are presented at the 69th American Academy of Neurology (AAN) Annual Meeting, in Boston, Massachusetts, USA.

The global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021. The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The report also includes a discussion of the key vendors operating in this market.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology alliance with ThromboGenics, a biopharmaceutical company focused on developing treatments for back of the eye disease.

Piramal Enterprises’ Consumer Products business has partnered with the Indian Pharmaceutical Association (IPA), to promote responsible self-care to over 5,000 chemists in India, starting in the Eastern region. In line with Piramal Group’s values of Knowledge, Action, Care and Impact, the initiative has been undertaken to provide educational information and spread awareness to pharmacists and the public on responsible self-care. IPA is the national professional body of pharmacists engaged in various facets of pharmacy.

Aptose Biosciences Inc  a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced that preclinical data for its pan-FLT3/BTK inhibitor CG’806 will be presented in two separate posters at the 2017 American Association for Cancer Research (AACR) Conference Hematologic Malignancies: Translating Discoveries to Novel Therapies, being held May 6-9 in Boston, MA.

Prime Minister Narendra Modi said that world health surveys have re-established the importance of hygiene, no one has paid much attention to preventive measures in health care in India, Adding that the mission of his government Swachh Bharat is a part of promoting health habits

Indian PM Narendra Modi at the dedication ceremony of Kiran Multispeciality Hospital in Surat Prime Minister Narendra Modi said his government could adopt a legal framework whereby doctors will have to prescribe cheaper generic medicines than brand-name drugs equivalent to Patients. Modi said his government adopted a health policy after 15 years and limited the prices of drugs and stents, which angered some pharmaceutical companies.

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso is the first and only approved medicine in the US indicated for NSCLC patients who have tested positive for the EGFR T790M mutation, and efficacy data suggest it may be a new standard of care for these patients.

Cipla Ltd, a global pharmaceutical company, today announced that its wholly owned subsidiary in USA — Cipla USA Inc. has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine1 patch for the management of Spasticity.